Avid Bioservices Inc (CDMO)

[north40000]

That guess is worth repeating, CJG...thank you:

"My guess is the 8-2017 “EnAbl” trademark has to do with the new Avid “Antibody Discovery Platform” SK talked about in the 7-14-17 CC, and was added to the 4-30-17 10-K iss. 7-14-17...

S.King 7-14-17: “Another part of our effort to attract new customers is to expand our service offerings. Our scientists have developed a state-of-the-art Antibody Discovery & Characterization Platform through which we can generate antibodies against virtually any target. These capabilities are meant to allow rapid screening for high affinity antibodies that are developable. These capabilities are a natural extension of the services we already offer through Avid and it represents an attractive way to bringing customers at a much earlier stage of development with the potential to move them quickly into process developments and cGMP manufacturing. . .
The Antibody Discovery Platform discussed earlier [Avid] could also be instrumental on the R&D side of the business, allowing us to rapidly identify antibodies against already validated targets, as well as the potential to identify novel targets. As we think about diversifying our development pipeline to include lower risk, already validated targets, this new capability could help us to identify developable antibodies that could have short-term value, as the need for such antibodies is on the rise. And this approach fits very well into our core capabilities and experience in the development of monoclonal antibodies. You can expect to hear more about this new capability over the coming months on both sides of our business.” http://tinyurl.com/yb4wulvu ...[more]"

See also:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136279744